|Bid||49.45 x 800|
|Ask||0.00 x 800|
|Day's range||49.17 - 49.80|
|52-week range||41.23 - 53.55|
|Beta (3Y monthly)||0.64|
|PE ratio (TTM)||20.10|
|Forward dividend & yield||1.25 (2.53%)|
|1y target est||57.90|
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
AstraZeneca made strides on Tuesday towards its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly. The British drugmaker said Farxiga was successful in reducing the risk of deadly heart attacks or disease progression in patients with a common form of heart failure in a clinical trial that could help win regulatory approval for its wider use.
Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement. "Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter," the company said. The securities lawsuit was filed by a number of shareholders who claims compensation worth a total of 11.785 billion Danish crowns (1.4 billion pounds) based on trading of Novo shares for two years from February 2015.
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
Novo Nordisk raised its sales forecast for this year thanks to growing demand for obesity drugs and a new injectable treatment for diabetes, now its growth engine as insulin sales decline. The Danish company is pinning its hopes on a relatively new treatment for type 2 diabetes as its older insulin drugs face political pressure over the soaring cost of the life-sustaining medicine in the United States. Sales of its new once-weekly injectable treatment, branded Ozempic, rose to 2.3 billion Danish crowns ($345 million) in the second quarter, which was higher than expected by analysts, sending shares in the world's top diabetes drugmaker 1.4% higher in early trading on Friday.
European shares slid on Friday with Italian stocks 2.5% lower on political uncertainty, while comments by U.S. President Donald Trump that he was not going to make a trade deal with China also weighed on sentiment. Italy's main index touched a two month low with its bank index tumbling 4.5% after the leader of the ruling League party, Matteo Salvini, pulled his support for the country's governing coalition on Thursday and called for fresh elections.
European shares fell on Friday, leading them to post a second straight week of losses, as worries about the stability of Italy's government rattled investors and concerns about Sino-U.S. trade tensions lingered. Milan's FTMIB index tumbled 1.6% with Italian banks hardest hit after the leader of the ruling League party, Matteo Salvini, pulled his support for the country's governing coalition on Thursday. Markets have recently been sensitive to political developments in Rome with Italian bond yields jumping each time there were doubts about the soundness of the government.
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...